Peptidream
36 articles about Peptidream
-
PeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates
9/20/2023
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced a new multi-target collaboration and license agreement with U.S.-based Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.
-
The Japanese biopharma will receive $40 million upfront from Genetech for R&D of its macrocyclic peptide-radioisotope drug conjugates, with another $1 billion on the line in milestone payments.
-
PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate
3/22/2023
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced the nomination of the second targeted peptide radiopharmaceutical clinical development candidate arising from their strategic partnership with RayzeBio, Inc., (“RayzeBio”), a privately held California-based targeted radiopharmaceutical company developing innovative cancer drugs.
-
PeptiDream Announces New Research and Collaboration Agreement with Lilly for the Discovery of Novel Peptide Drug Conjugates
12/27/2022
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced that they have entered into a Research Collaboration and License Agreement with US-based Eli Lilly and Company focused on the discovery and development of novel peptide drug conjugates.
-
PeptiDream Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Peptide Drug Conjugates
12/27/2022
PeptiDream Inc. announced a new multi-target collaboration and license Agreement with U.S.-based Merck & Co, Inc., Rahway, N.J., U.S.A., known as “MSD” outside the U.S. and Canada, through a subsidiary, focused on the discovery and development of novel peptide drug conjugates.
-
Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline
9/9/2021
Amolyt Pharma and PeptiDream Inc. announced that Amolyt Pharma has exercised its option to globally license a portfolio of macrocyclic peptide growth hormone receptor antagonists under the terms of its research collaboration agreement with PeptiDream announced in December 2020.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
-
Fujitsu's Quantum-Inspired Digital Annealer technology applied to drug discovery process to streamline the search for candidate compounds
9/25/2019
Fujitsu Limited and PeptiDream Inc. has announced that they have agreed to initiate joint research and development in the area of peptide drug discovery, using Fujitsu's Digital Annealer, which employs next-generation computing architecture to quickly solve combinatorial optimization problems.
-
Fujitsu and PeptiDream Leverage Quantum-Inspired Tech in Joint Research to Accelerate Drug Discovery
9/25/2019
Fujitsu's Quantum-Inspired Digital Annealer technology applied to drug discovery process to streamline the search for candidate compounds
-
PeptiDream Announces New Peptide Drug Conjugate (“PDC”) Collaboration Agreement with Novartis
6/27/2019
PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today a new Peptide Drug Conjugate “PDC” collaboration agreement with Swiss-based Novartis (“Novartis”)
-
Kleo Pharmaceuticals Announces a CD38 Targeting Antibody Recruiting Molecule (ARM™) to Treat Multiple Myeloma as the First Clinical Candidate in its Partnership with PeptiDream
6/18/2019
Kleo Pharmaceuticals, Inc. announced that CD38-ARM, a CD38 targeting antibody recruiting molecule to treat multiple myeloma, will be its first product candidate to move into the clinic with anticipated human studies to commence in 2020.
-
PeptiDream Announces Strategic Partnership with Drug-Delivery Expert PharmaIN
6/6/2019
PeptiDream Inc., a public Kanagawa-based biopharmaceutical company announced a strategic partnership with Seattle-based PharmaIN Corporation for the purpose of investigating the use of PharmaIN's proprietary drug carrier and delivery Protected Graft Co-Polymer technology in combination with PeptiDream's peptide discovery and development programs.
-
PeptiDream Announces New Peptide Drug Conjugate (PDC) Discovery Deal with Shionogi
1/23/2019
Peptidream announced that it has entered into a multi-program collaborative research agreement with Osaka-based Shionogi & Co., Ltd for the discovery and development of a series of blood brain barrier (BBB) penetrating peptide drug-conjugates (PDCs).
-
PeptiDream Announces Drug Discovery and Development Agreement with Santen Pharmaceutical
9/26/2018
PeptiDream Inc. announced today that it has entered into a broad-based multi-target discovery and development agreement with Osaka-based Santen Pharmaceuticals Co., Ltd., (“Santen”).
-
PeptiDream Announces the Appointment of Dr. Kiyofumi Kaneshiro to the Management Team at PeptiDream Inc.
1/12/2018
PeptiDream announced today, the appointment of Dr. Kiyofumi Kaneshiro to the management team at PeptiDream.
-
Peptidream has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets.
-
Peptidream And Kleo Announce Collaboration Agreement To Develop Novel Immunotherapies For Oncology
7/18/2017
-
Heptares And Peptidream Enter Strategic Collaboration To Discover, Develop And Commercialise Novel Therapeutics In Inflammatory Disease
6/29/2017
-
Peptidream Announces Licensing Of Peptide Discovery Platform System (PDPS) Technology To Shionogi
6/12/2017